Litigation Details for Novo Nordisk Inc. v. Rio Biopharmaceuticals, Inc. (D. Del. 2022)

✉ Email this page to a colleague

The small molecule drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2022-03-04	1	Complaint	United States Patent Nos. 8,129,343 (the “’343 patent”), 9,132,239 (the “’239 patent”), 9,457,154 (the… COUNT FOR INFRINGEMENT OF U.S. PATENT NO. 9,132,239 33. Novo Nordisk re-alleges…(the “’154 patent”), 9,687,611 (the “’611 patent”), and 10,335,462 (the “’462 patent”) which cover inter… 1. This is an action for patent infringement under the patent laws of the United States, Title… THE PATENTS-IN-SUIT 15. On March 6, 2012, the United States Patent and Trademark	External link to document
2022-12-21	101	Notice of Service	U.S. Patent Nos. 8,129,343; 8,536,122; 8,114,833; 8,920,383; 9,775,953; 9,457,154; and 10,335,462 filed… 4 March 2022 1:22-cv-00294 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2023-08-02	161	Notice of Service	Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 8,114,833; 8,920,383; 9,775,953; 9,457,… 4 March 2022 1:22-cv-00294 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document